scholarly journals Metastatic lung adenocarcinoma in appearance of diminutive colonic polyp

2015 ◽  
Vol 6 (1) ◽  
Author(s):  
Bora Aktaş ◽  
Ferdane Sapmaz ◽  
Sebahat Başyiğit ◽  
Metin Uzman

Although about 50% of lung cancers have distant metastasis at the time of initial diagnosis, colonic metastases are extremely rare. This report presents a rare clinical case of colonic metastasis from primary adenocarcinoma of the lung.

2018 ◽  
Vol 25 ◽  
pp. 86-88
Author(s):  
Stylianos Vittorakis ◽  
Georgia Giannakopoulou ◽  
Konstantinos Konstantinides ◽  
Anna Daskalaki ◽  
Konstantinos Samitas

2012 ◽  
Vol 107 ◽  
pp. S459
Author(s):  
Razvi Razack ◽  
Nishith Patel ◽  
Shamik Shah ◽  
Dharmesh Kaswala ◽  
Zamir Brelvi

2017 ◽  
Vol 112 ◽  
pp. S992
Author(s):  
Mohammad Maysara Asfari ◽  
Thomas Plesec ◽  
Prashanthi N. Thota

2012 ◽  
Vol 44 (6) ◽  
pp. e11 ◽  
Author(s):  
Paolo Pozzato ◽  
Angela Salerno ◽  
Alessandra Cancellieri ◽  
Maurizio Ventrucci

2013 ◽  
Vol 5 (4) ◽  
pp. 306 ◽  
Author(s):  
ShamikS Shah ◽  
RazviM Razack ◽  
ValerieA Fitzhugh ◽  
ZamirS Brelvi ◽  
DharmeshH Kaswala ◽  
...  

Apmis ◽  
2016 ◽  
Vol 124 (5) ◽  
pp. 384-392 ◽  
Author(s):  
Gudrun Nina Oskarsdottir ◽  
Johannes Bjornsson ◽  
Steinn Jonsson ◽  
Helgi J Isaksson ◽  
Tomas Gudbjartsson

2021 ◽  
Vol 49 (9) ◽  
pp. 030006052110446
Author(s):  
Xue Pan ◽  
Anyuan Zhong ◽  
Yufei Xing ◽  
Xi Li ◽  
Haiwei Du ◽  
...  

Anaplastic lymphoma kinase ( ALK) rearrangement occurs in approximately 5% of non-small cell lung cancers (NSCLCS), and EML4-ALK is the most commonly observed ALK fusion variant in NSCLC. However, growth hormone receptor ( GHR) as the fusion partner for ALK and the clinical response to ALK tyrosine kinase inhibitors in patients with metastatic lung adenocarcinoma (LUAD) who carry the GHR-ALK variant have not been documented. This case describes a 63-year-old woman diagnosed with metastatic LUAD. Immunohistochemistry revealed positive ALK expression, and the patient was treated with crizotinib. After 3 weeks of treatment, the patient had a partial response. Because of treatment-related adverse events, the dose of crizotinib was reduced. After 3.7 months, computed tomography uncovered disease progression. Next-generation sequencing identified a novel GHR-ALK fusion in the plasma of the patient. The patient was treated again with crizotinib, but the disease progressed again 2 months later. Then, the patient received chemotherapy. She succumbed to her disease 11 months after the initial diagnosis. Our work provides evidence supporting the use of crizotinib in patients with metastatic LUAD harboring GHR-ALK.


2018 ◽  
Vol 2 ◽  
pp. 14-14
Author(s):  
Prashanthi N. Thota ◽  
Thomas Plesec

2020 ◽  
Author(s):  
Shahan Mamoor

Non-small cell lung adenocarcinoma (NSCLC) is a leading cause of death in the United States and worldwide (1, 2). We mined published microarray data (3, 4, 5) to discover genes associated with NSCLC. We identified significant differential expression of the tyrosine kinase TEK in tumors from patients with NSCLC. TEK may be of relevance to the initiation, progression or maintenance of non-small cell lung cancers.


Sign in / Sign up

Export Citation Format

Share Document